Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
about
Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactomeAndrogen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cellsRaloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.Androgen and its receptor promote Bax-mediated apoptosisTranscription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target?Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsAndrogens as therapy for androgen receptor-positive castration-resistant prostate cancer.Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.Cytosolic sulfotransferase 2B1b promotes hepatocyte proliferation gene expression in vivo and in vitro.Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition.AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.Effect of serum testosterone and percent tumor volume on extra-prostatic extension and biochemical recurrence after laparoscopic radical prostatectomyCaffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signalingCholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cellsThe diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosisMathematical modelling of prostate cancer growth and its application to hormone therapy.Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?Testosterone Therapy in Men With Prostate Cancer.The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.Saurolactam Inhibits Proliferation, Migration, and Invasion of Human Osteosarcoma Cells.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.
P2860
Q24294625-E8D7F7C0-4AE6-4C95-8BD8-D74EF61C23E4Q33607836-95501CFB-0AB9-4932-A953-7FFE2F0CF700Q34124650-0D5F6049-C0B7-46D9-B92A-407128A82CD1Q34278855-2214990C-5B2F-4D36-AAB2-B7F62CB3C8E2Q34306116-4A170698-7532-4629-BF0C-C776AD71E64AQ34502268-0019E229-DEAC-478E-93EA-AEC4C5161E78Q34519663-78761394-CB71-4899-9AC5-7CD89816BB0DQ35053261-128E9924-AC44-4B56-ADCC-6E0E9339D22EQ35070404-E250A02B-2319-401D-94D1-A48EF7BD07F4Q35207110-B0DBDD5C-121C-4C73-9C99-4DE1AFFD4A4DQ35434843-33042F25-C95B-4DFC-B66E-34FFF6DD0CA1Q35740051-9593BE9F-0A03-4CE5-BA75-703D324250B0Q36175918-DE37B3AC-A952-4D17-86B7-02151DCFEEB7Q36317900-93A2BFE4-66B9-42B0-A2BC-1031456CB8A4Q36413704-A765780E-ACD6-4339-86A4-9645C8996836Q36530243-232B8A96-A452-41A2-B810-7CA189CE10ACQ36790229-00AC607A-ED06-4A98-ACA0-D8B78959169EQ36926791-1F2EBA80-D956-4AB6-87C2-08810C3FB284Q37074725-A1340233-3041-4F98-ADE0-9042C3DA6544Q37130094-F377B8AE-A4E6-4E11-B0E9-4560505303DDQ37219788-379065C9-044B-4631-BC53-5D9E68F33AE4Q37389886-28AB6C66-3D76-47E1-A5F7-FC8ACCA37774Q37431953-F11B25E7-EFF9-4837-8DDE-4AC1DC8E43FBQ37797777-176A2C5A-FF34-4155-8DD7-AC2849791B03Q37868755-237C11C4-C953-44BB-BFDB-B8C59362A191Q38087885-B192ED98-FE85-407E-9FFF-FD046228FB63Q38256395-3F716A59-1587-4B1A-9E33-99DA0494B746Q38683604-3027EACB-BD19-46D0-B4EA-9E2D24FAAEACQ38810776-A9979C84-0B67-4834-A2D4-78B3B9F68254Q38828800-DA4B9881-49C8-4820-851E-3F1F06E88CCAQ38915850-4705BB30-181A-47EB-87A0-7261FEA52D21Q39016544-935A8200-705E-4959-B631-D6D4174735C0Q39123647-79F6D15C-C635-48EF-990A-1BF618EC2503Q39190804-CE594210-CC81-4ACF-8EB6-3295C14F4169Q39433008-73A284E8-FAFF-4253-B7E4-D8A31D124EF4Q41072868-25B6BABB-894B-4E87-997E-961A1D7627D5Q46147831-DE8C5D9D-9BE2-4A2A-BF7A-C9CF84FF9C9FQ47191382-6DFA34B7-4352-4B5E-BC02-58AB427060D4Q47359141-BF863892-1DE2-4E78-BA60-C4C86E43753BQ55096243-39A5C8E8-8EA6-4D1C-820F-F2B7C0A237E9
P2860
Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Androgen causes growth suppres ...... ted phenotype in athymic mice.
@en
type
label
Androgen causes growth suppres ...... ted phenotype in athymic mice.
@en
prefLabel
Androgen causes growth suppres ...... ted phenotype in athymic mice.
@en
P2093
P1433
P1476
Androgen causes growth suppres ...... ted phenotype in athymic mice.
@en
P2093
Chih-pin Chuu
John M Kokontis
Junichi Fukuchi
Richard A Hiipakka
Shutsung Liao
P304
P356
10.1158/0008-5472.CAN-04-3992
P407
P577
2005-03-01T00:00:00Z